



**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	87,950	(2)	I	Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	21,987	(2)	I	Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	297,636	(2)	I	Sanderling IV Biomedical Co-Investment Fund, L.P.
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	478	(2)	I	Sanderling V Beteiligungs GmbH & Co. KG
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	1,993	(2)	I	Sanderling V Biomedical Co-Investment Fund, L.P.>
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	548	(2)	I	Sanderling V Limited Partnership
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	52,925	(2)	I	Sanderling Venture Partners II, L.P.
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	185,765	(2)	I	Sanderling Venture Partners IV Co-Investment Fund, L.P.
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	3,288	(2)	I	Sanderling Venture Partners V Co-Investment Fund, L.P.
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	19,441	(2)	I	Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	3,527	(2)	I	Sanderling Ventures Management V
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	4,860	(2)	I	Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	166,410	(2)	I	Sanderling IV Biomedical Co-Investment Fund, L.P.
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	33,186	(2)	I	Sanderling Venture Partners II, L.P.
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	38,402	(2)	I	Sanderling Venture Partners IV Co-Investment Fund, L.P.

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	12,190	(2)	I	Sanderling Management Limited, Cust. FBO Sanderling Ventures Limited, L.P.
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	3,047	(2)	I	Sanderling Management Limited, Cust. FBO Middleton-McNeil, L.P.
Series D-1 Convertible Preferred Stock	(1)	(1)	Common Stock	33,455	(2)	I	Sanderling V Beteiligungs GmbH & Co. KG
Series D-1 Convertible Preferred Stock	(1)	(1)	Common Stock	139,397	(2)	I	Sanderling V Biomedical Co-Investment Fund, L.P.

**Explanation of Responses:**

1. All Series of the Issuer's Convertible Preferred Stock are convertible into common stock upon demand at any time.
2. 1-for-3.6.

**Remarks:**

This is the first of three Forms 3 filed by the reporting person on the August 11, 2004.

/s/ Fred A. Middleton

08/04/2004

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.